The abstract is read at the publisher; the summary is JClub's.
Typhoid fever in Ibadan, Nigeria is linked to mean incremental total costs of $42 (95% CI 18–71) versus matched malaria controls, with higher inpatient costs.
- Why it matters: Evidence on the economic burden of typhoid fever in sub-Saharan Africa is limited, limiting locally grounded decisions on prevention and resource allocation.
- What they did: A field-based cost-of-illness study enrolled 198 participants at six healthcare facilities from 2022–2025, matching cases to malaria controls by age group, sex, and point of care. Costs were estimated for direct medical, direct non-medical, and indirect components and converted to US dollars using year-specific exchange rates.
- The result: Average total costs per episode were $130 for S. Typhi, and for S. Typhi were $309 for inpatients versus $72 for outpatients; incremental costs versus malaria were $42 (95% CI 18–71) for S. Typhi, $104 (95% CI 25–197) for iNTS, and $560 (95% CI 289–882) for special perforation cases.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.